Jeffrey D. Kent

9.6k total citations · 4 hit papers
60 papers, 7.2k citations indexed

About

Jeffrey D. Kent is a scholar working on Pharmacology, Genetics and Surgery. According to data from OpenAlex, Jeffrey D. Kent has authored 60 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pharmacology, 15 papers in Genetics and 14 papers in Surgery. Recurrent topics in Jeffrey D. Kent's work include Inflammatory mediators and NSAID effects (17 papers), Inflammatory Bowel Disease (14 papers) and Microscopic Colitis (11 papers). Jeffrey D. Kent is often cited by papers focused on Inflammatory mediators and NSAID effects (17 papers), Inflammatory Bowel Disease (14 papers) and Microscopic Colitis (11 papers). Jeffrey D. Kent collaborates with scholars based in United States, Germany and France. Jeffrey D. Kent's co-authors include William J. Sandborn, Remo Panaccione, Paul Rutgeerts, Ju Li, Paul F. Pollack, Kenneth M. Verburg, Stefan Schreiber, Andrew Whelton, J B Lefkowith and Jay L. Goldstein and has published in prestigious journals such as JAMA, Journal of Biological Chemistry and Annals of Internal Medicine.

In The Last Decade

Jeffrey D. Kent

60 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis

2000 2.4k citations Fred E. Silverstein, Gerald A. Faich et al. JAMA profile →
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial

2006 1.7k citations Jean–Frédéric Colombel, William J. Sandborn et al. Gastroenterology profile →
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial

2007 798 citations William J. Sandborn, S. B. Hanauer et al. Gut profile →
Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab

2007 740 citations William J. Sandborn, Paul Rutgeerts et al. Annals of Internal Medicine profile →

Peers

Jeffrey D. Kent

GENET

EPIDE

PHARM

SURGE

IMMUN

Yutaka Kawahito Japan

Christopher J. Sinal Canada

Saulo Klahr United States

Christa Buechler Germany

Pierre Gourdy France

Per‐Arne Svensson Sweden

Richard C. Hubbard United States

W. Creutzfeldt Germany

Olavi Ylikorkala Finland

Michael L. Steer United States

Yutaka Kawahito Japan

Jeffrey D. Kent

900 ×0.3

GENET

948 ×0.3

EPIDE

1.5k ×0.7

PHARM

508 ×0.3

SURGE

929 ×0.9

IMMUN

Citations per year, relative to Jeffrey D. Kent Jeffrey D. Kent (= 1×) peers Yutaka Kawahito

Countries citing papers authored by Jeffrey D. Kent

Since Specialization

Citations

This map shows the geographic impact of Jeffrey D. Kent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey D. Kent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey D. Kent more than expected).

Fields of papers citing papers by Jeffrey D. Kent

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey D. Kent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey D. Kent. The network helps show where Jeffrey D. Kent may publish in the future.

Co-authorship network of co-authors of Jeffrey D. Kent

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey D. Kent. A scholar is included among the top collaborators of Jeffrey D. Kent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey D. Kent. Jeffrey D. Kent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brigham, Mark D., Jeffrey D. Kent, Brian LaMoreaux, et al.. (2019). Prevalence of Gout in the Surviving United States Solid Organ Transplantation Population. Transplantation Proceedings. 51(10). 3449–3455. 8 indexed citations

Brigham, Mark D., et al.. (2019). Gout Severity in Recipients of Kidney Transplant. Transplantation Proceedings. 51(6). 1816–1821. 9 indexed citations

Sandborn, William J., Paul Rutgeerts, Robert Enns, et al.. (2015). Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab. Annals of Internal Medicine. 10 indexed citations

Alten, Rieke, Robert J. Holt, Amy Grahn, et al.. (2015). Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone. Scandinavian Journal of Rheumatology. 44(5). 354–358. 13 indexed citations

Kent, Jeffrey D., et al.. (2015). Efficacy and safety of diclofenac sodium 2% topical solution for osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled, 4 week study. Current Medical Research and Opinion. 32(2). 241–250. 28 indexed citations

Holt, Robert J., John G. Fort, Amy Grahn, Jeffrey D. Kent, & Alfonso E. Bello. (2015). Onset and durability of pain relief in knee osteoarthritis: Pooled results from two placebo trials of naproxen/esomeprazole combination and celecoxib. The Physician and Sportsmedicine. 43(3). 200–212. 12 indexed citations

Holt, Robert J., et al.. (2015). Bioequivalence of diclofenac sodium 2% and 1.5% topical solutions relative to oral diclofenac sodium in healthy volunteers. Postgraduate Medicine. 127(6). 581–590. 12 indexed citations

Holt, Robert J., et al.. (2013). Budget Impact Modeling for a Single-Tablet Formulation of Ibuprofen and Famotidine for Prevention of Upper Gastrointestinal Ulcers in Patients With Osteoarthritis and/or Rheumatoid Arthritis. Clinical Therapeutics. 35(3). 321–332. 8 indexed citations

Colombel, J F, David A. Schwartz, William J. Sandborn, et al.. (2009). Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut. 58(7). 940–948. 254 indexed citations

10.

Sandborn, William J., S. B. Hanauer, P. Rutgeerts, et al.. (2007). Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 56(9). 1232–1239. 798 indexed citations breakdown →

11.

Sandborn, William J., P. Rutgeerts, Robert Enns, et al.. (2006). Adalimumab Rapidly Induces Clinical Remission and Response in Patients with Moderate to Severe Crohnʼs Disease Who Had Secondary Failure to Infliximab Therapy. The American Journal of Gastroenterology. 101. S448–S448. 19 indexed citations

12.

Schwartz, David A., Paul Rutgeerts, J F Colombel, et al.. (2006). Induction, Maintenance, and Sustainability of the Healing of Draining Fistulas in Patients with Crohnʼs Disease Treated with Adalimumab. The American Journal of Gastroenterology. 101. S458–S459. 3 indexed citations

13.

Colombel, Jean–Frédéric, William J. Sandborn, Paul Rutgeerts, et al.. (2006). Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial. Gastroenterology. 132(1). 52–65. 1655 indexed citations breakdown →

14.

Chabot, Christopher C., Jeffrey D. Kent, & Winsor H. Watson. (2004). Circatidal and Circadian Rhythms of Locomotion inLimulus polyphemus. Biological Bulletin. 207(1). 72–75. 32 indexed citations

15.

Goldstein, Jay L., Glenn M. Eisen, N M Agrawal, et al.. (2004). Reduced incidence of upper gastrointestinal ulcer complications with the COX‐2 selective inhibitor, valdecoxib. Alimentary Pharmacology & Therapeutics. 20(5). 527–538. 39 indexed citations

16.

Sikes, David, Naurang M. Agrawal, William W. Zhao, et al.. (2002). Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. European Journal of Gastroenterology & Hepatology. 14(10). 1101–1111. 88 indexed citations

17.

Silverstein, Fred E., Gerald A. Faich, Jay L. Goldstein, et al.. (2000). Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis. JAMA. 284(10). 1247–1247. 2401 indexed citations breakdown →

18.

Fornari, Victor, et al.. (1994). Anorexia nervosa: “Thirty something”. Journal of Substance Abuse Treatment. 11(1). 45–54. 15 indexed citations

19.

Burke, Robert E., et al.. (1991). Unilateral hypoxic-ischemic injury in neonatal rat results in a persistent increase in the density of striatal tyrosine hydroxylase immunoperoxidase staining. Developmental Brain Research. 58(2). 171–179. 35 indexed citations

20.

Kent, Jeffrey D., Michael Koban, & C. Ladd Prosser. (1988). Cold-acclimation-induced protein hypertrophy in channel catfish and green sunfish. Journal of Comparative Physiology B. 158(2). 185–198. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact